Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

ASTRAZENECA (AZN)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

AstraZeneca : Top AstraZeneca shareholder Woodford adds to stake, bullish on outlook

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/17/2017 | 10:43am CEST
A sign is seen at an AstraZeneca site in Macclesfield

Top AstraZeneca (>> AstraZeneca plc) shareholder Woodford Investment Management said on Wednesday it had added to its stake in the pharmaceutical firm and was confident in its growth outlook.

Top AstraZeneca (>> AstraZeneca plc) shareholder Woodford Investment Management said on Wednesday it had added to its stake in the pharmaceutical firm and was confident in its growth outlook.

Woodford, in an update on its website, said shares in AstraZeneca had been unfairly hit since analysts raised concern about the prospects for its key cancer drug trial, Mystic, after rival Bristol-Myers Squibb (>> Bristol-Myers Squibb Co) scaled back its plans in a similar area.

"Whilst this is understandable to an extent, we think the reaction is wrong. Indeed, Bristol-Myers Squibb’s problems in this setting may well turn out to be positive for AstraZeneca," Mitchell Fraser-Jones said in a note to investors.

Fraser-Jones said Woodford believed AstraZeneca was on a path to return to growth regardless of the outcome of Mystic, although it was nevertheless optimistic that Mystic would be successful when results are released later this year.

(Adds dropped word "trial" in second paragraph.)

(Reporting by Simon Jessop; Editing by Susan Fenton)

Stocks treated in this article : Bristol-Myers Squibb Co, AstraZeneca plc
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTRAZENECA
01:01p ASTRAZENECA : US FDA Accepts Supplemental Biologics License Application for IMFI..
11:09aDJHUTCHISON CHINA MEDITECH : AstraZeneca Say Drug Shows Potential to Treat Lung Ca..
08:46aDJASTRAZENECA : FDA Accepts Imfinzi Supplemental Biologics License Application; Gr..
08:12a ASTRAZENECA : US FDA accepts supplemental Biologics License Application for Imfi..
08:01a ASTRAZENECA : FDA accepts sBLA file for Imfinzi; priority review
10/16 ASTRAZENECA : Pharma and medtech industries prepare for hard Brexit
10/16 ASTRAZENECA : How will the life sciences strategy affect businesses?
10/16 ASTRAZENECA : shares its comprehensive scientific approach at the World Conferen..
10/16 ASTRAZENECA : Tech startup LifeWallet helps consumers take control of their heal..
10/14 ASTRAZENECA : Faslodex (fulvestrant) receives positive chmp opinion for the trea..
More news
News from SeekingAlpha
10:00a Featured Stocks In October's Most Attractive/Most Dangerous Model Portfolios
07:03a FDA accepts AstraZeneca's marketing application for expanded use of Imfinzi
10/16 Merck's Risk/Reward Is Compelling
10/16 AURINIA PHARMACEUTICALS : An Under $10 Biotech Stock To Keep An Eye On
10/16 President Trump at it again with comments on "out of control" drug prices
Financials ($)
Sales 2017 21 545 M
EBIT 2017 5 803 M
Net income 2017 2 561 M
Debt 2017 12 230 M
Yield 2017 3,99%
P/E ratio 2017 31,07
P/E ratio 2018 26,12
EV / Sales 2017 4,59x
EV / Sales 2018 4,53x
Capitalization 86 688 M
Chart ASTRAZENECA
Duration : Period :
AstraZeneca Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 32
Average target price 66,4 $
Spread / Average Target -2,8%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA15.54%86 688
JOHNSON & JOHNSON18.42%365 346
NOVARTIS13.23%226 956
ROCHE HOLDING LTD.5.20%215 359
PFIZER11.88%214 265
MERCK AND COMPANY7.68%172 751